Artemether ameliorates adriamycin induced cardiac atrophy in mice.
Mol Med Rep
; 28(2)2023 Aug.
Article
in En
| MEDLINE
| ID: mdl-37387406
ABSTRACT
Adriamycin is a widely used and effective antitumor drug; however, its application is limited by various side effects, including irreversible cardiotoxicity. The central role of cardiac atrophy in Adriamycininduced cardiotoxicity has been revealed; however, the underlying mechanism of this process remains unclear. Artemether is a wellknown Chinese herbal medicine, and its pharmacological action is related to the regulation of mitochondrial function and redox status. The present study determined the effects of artemether on Adriamycininduced cardiotoxicity and investigated the underlying mechanisms. After mouse model establishment and artemether intervention, experimental methods including pathological staining, immunohistochemistry, immunofluorescence, immunoblotting, ELISA and reverse transcriptionquantitative PCR were used to evaluate the therapeutic effect. The results demonstrated that artemether prevented Adriamycininduced cardiac atrophy and recovered the intercombination of connexin 43 and Ncadherin at the intercalated discs. Artemether also regulated the autophagy pathway and restored the unbalanced ratio of Bax and Bcl2 in myocardial cells. In addition, the increased serum H2O2 levels after Adriamycin exposure were significantly decreased by artemether, and the mitochondrial alterations and redox imbalance in myocardial cells were also improved to varying degrees. In summary, the findings of the present study provide reliable evidence that artemether could ameliorate cardiac atrophy induced by Adriamycin. This therapeutic approach may be translated to the clinic for preventing druginduced heart diseases.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Doxorubicin
/
Cardiotoxicity
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Mol Med Rep
Year:
2023
Document type:
Article